ascopubs.org

Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy

Patient Assessment of Bowel Function During and After Pelvic Radiotherapy: Results of a Prospective Phase III North Central Cancer Treatment Group Clinical Trial Consecutive patients were ...
Benzinga.com

Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial

On Saturday, Johnson & Johnson (NYSE: JNJ) shared new longer follow-up results from the Phase 1b/2 OrigAMI-1 study. The trial is evaluating Rybrevant (amivantamab-vmjw) in combination with FOLFOX or ...
Seeking Alpha

RYBREVANT® (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Pivotal Phase 3 studies, including the global, randomized OrigAMI-2 and OrigAMI-3 studies evaluating subcutaneous amivantamab with FOLFOX and FOLFIRI, are underway to further evaluate the potential of ...
ascopubs.org

Comparison between nivolumab plus ipilimumab, FOLFOX and nivolumab plus FOLFOX therapy as first-line treatment for cisplatin-unfit advanced esophageal squamous cell carcinoma.

Three-year and five-year outcomes of a phase II study of perioperative CapeOx therapy for advanced gastric cancer with extensive lymph node metastasis (OGSG1701). Trifluridine/tipiracil and ...